Evidence map›Paper›PMID 20590641›Full record

ArticleBritish journal of pharmacology2010

Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide.

J-F Desaphy, A Dipalma, T Costanza, C Bruno, G Lentini, C Franchini, Al George, D Conte Camerino

Open access · greenAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prokaryotic NavMs channel as a structural and functional model for eukaryotic sodium channel antagonism.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

J-F DesaphyDepartment of Pharmacobiology, University of Bari, Bari, Italy. jfdesaphy@farmbiol.uniba.it
A Dipalma
T Costanza
C Bruno
G Lentini
C Franchini
Al George
D Conte Camerino
University of Bari Aldo Moro · ITVanderbilt University · US

Funding

HEREDITARY DEFECTS IN HUMAN SODIUM CHANNELSR01NS032387 · NINDS · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L. · 1994 to 2015
$3.2M
Hereditary Defects in Human Sodium ChannelsR37NS032387 · NINDS · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L. · 2003 to 2009
$2.6M
NINDS NIH HHS NS032387NINDS NIH HHS R01 NS032387NINDS NIH HHS R37 NS032387Telethon GGP04140
6 · The paper itself

Abstract

background and purposePilsicainide, an anti-arrhythmic drug used in Japan, is described as a pure sodium channel blocker. We examined the mechanisms by which it is able to block open channels, because these properties may be especially useful to reduce hyperexcitability in pathologies characterized by abnormal sodium channel opening. EXPERIMENTAL APPROACH: The effects of pilsicainide on various heterologously expressed human sodium channel subtypes and mutants were investigated using the patch clamp technique. KEY

resultsPilsicainide exhibited tonic and use-dependent effects comparable to those of mexiletine and flecainide on hNav1.4 channels. These use-dependent effects were abolished in the mutations F1586C and Y1593C within segment 6 of domain IV, suggesting that the interaction of pilsicainide with these residues is critical for its local anaesthetic action. Its affinity constants for closed channels (K(R)) and channels inactivated from the closed state (K(I)) were high, suggesting that its use-dependent block (UDB) requires the channel to be open for it to reach a high-affinity blocking site. Accordingly, basic pH, which slightly increased the proportion of neutral drug, dramatically decreased K(R) and K(I) values. Effects of pilsicainide were similar on skeletal muscle hNav1.4, brain hNav1.1 and heart hNav1.5 channels. The myotonic R1448C and G1306E hNav1.4 mutants were more and less sensitive to pilsicainide, respectively, due to mutation-induced gating modifications. CONCLUSIONS AND IMPLICATIONS: Although therapeutic concentrations of pilsicainide may have little effect on resting and closed-state inactivated channels, it induces a strong UDB due to channel opening, rendering the drug ideally suited for inhibition of high-frequency action potential firing.

Indexed as

BrainCell LineFlecainideHeartHumansLidocaineMexiletineMuscle ProteinsMuscle, SkeletalNAV1.1 Voltage-Gated Sodium ChannelNAV1.4 Voltage-Gated Sodium ChannelNAV1.5 Voltage-Gated Sodium ChannelNerve Tissue ProteinsPatch-Clamp TechniquesSodium Channel BlockersSodium ChannelsFlecainideLidocaineMexiletineMuscle ProteinsNAV1.1 Voltage-Gated Sodium ChannelNAV1.4 Voltage-Gated Sodium ChannelNAV1.5 Voltage-Gated Sodium ChannelNerve Tissue ProteinspilsicainideSCN1A protein, humanSCN4A protein, humanSCN5A protein, humanSodium Channel BlockersSodium Channels

Identifiers

PMID20590641
PMCPMC2938822
OpenAlexW1687247837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.